
price close busi april
develop manufactur market devic
instrument orthoped specialti
biomed devic servic
execut support lofti valuat pt
bottom line maintain buy rate follow result beat cg/
street expect top bottom line sale y/i
organ came cg/consensu strength
driven momentum across entir portfolio especi knee mako
instrument neurotech adjust ep well cg/consensu
compani benefit top-lin beat oper
net net result reinforc thesi continu deliv msd
organ revenu growth continu take market share across board
begin benefit meaning halo effect mako placement someth
expect continue/acceler note underli new product cycl
medsurg ortho/recon support fundament momentum across
market -- someth feel lost major mako-focus investor
sum ye share expens ep howev expect best class
execut new product cycl drive upsid bia estim remain
revenu detail chang exclud impact adopt stryker
report sale growth organ despit less sell day
neg impact support us sale growth
sale growth xfx orthoped grew strong perform us
knee ou knee xfx us trauma/extrem medsurg
continu solid growth driven strength endoscopi medic
respect neurotech spine also strong post
growth driven demand neurotech product off-set soft global
guidanc increas organ revenu guidanc
y/i -- someth think posit upsid given on-going
momentum across us ortho medsurg neurotech heel new product
launch mako adopt adjust ep expect rang
mako place mako system global y/i inclus
system place us upgrad system exit
quarter mako system upgrad manag highlight
mako procedur repres
mako procedur perform capit rep abl focu
system placement rather upgrad abl place
system competit account account q/q reinforc
thesi competit share gain across entir product portfolio manag note
total knee sale continu grow faster account mako tka system
compar without lastli note place mako
exist account demonstr earli natur opportun
potenti continu momentum beyond -- opportun
becom confid follow recent dilig robot link
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
factset compani report canaccord genuiti estim
guidanc chang estim given better expect result
increas full-year organ revenu growth guidanc rang
previous accordingli adjust
ep guidanc increas rang
adjust ep expect rang made
follow chang estim
chang estim
adjust revenu estim
adjust pro forma ep
maintain revenu estim adjust
pro forma ep estim
maintain revenu estim adjust
pro forma ep estim
adjust revenu estim
adjust pro forma ep estim
adjust revenu estim
adjust pro forma ep estim
adjust revenu estim
adjust pro forma ep estim
buy unchang target price april
biomed devic servic
performanceactualcg estbeat/missconsensusbeat/missnet good gross special oper ex chg pro-forma oper net ep ex one-tim chg result categoryactualcg net sale
figur chang estim
large-cap medic devic comp group trade mean price-to-earnings multipl
given consist execut strong growth profil high end
peer group think stock justifi premium comp group sum
increas price target price target util
multipl appli pro-forma ep estim
figur matrix discount rate impli share price target
stryker
one world lead medic technolog compani
broadly-bas rang product orthoped signific presenc
medic specialti compani product includ implant use joint
replac trauma spinal surgeri surgic equip surgic
navig system endoscop commun system patient handl
emerg medic equip medic devic product use varieti
buy unchang target price april
biomed devic servic
oldnew oldnew oldnew net good gross special oper ex chg forma oper net ep ex one-tim chg pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl forma figur stryker incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price april
biomed devic servic
stryker corpor quarterli incom statementcanaccord genuiti kyle except per share good technolog special oper ex chg oper ex chg erest incom incom incom ex one-tim chg incom ex one-tim ep ex one-tim chg ep ex acq relat gross oper ex chg oper ex chg ex net charg net ex one-tim growth oper net incom charg ep charg ep ex acq growth net incom charg ep charg ep ex acq
buy unchang target price april
biomed devic servic
stryker corpor revenu mixcanaccord genuiti kyle mix us y/i y/i xfx/x q/q q/q mixdomest stryker
